Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D'Cruz CM.
Ladd B, et al. Among authors: bihani t.
Oncotarget. 2016 Aug 23;7(34):54120-54136. doi: 10.18632/oncotarget.10852.
Oncotarget. 2016.
PMID: 27472462
Free PMC article.